FDA Clears Tildrakizumab (Ilumya) for Plaque Psoriasis

Tildrakizumab-asmn, a selective interleukin-23 p19 inhibitor given by subcutaneous injection, was shown to be effective for chronic plaque psoriasis in two phase 3 trials.
FDA Approvals

http://ift.tt/2puzZwu